Johnson & Johnson’s Imaavy (nipocalimab) has become the first FDA-approved therapy for warm autoimmune hemolytic anemia (wAIHA) — a rare disease in which the immune system mistakenly destroys the body’s own red blood cells.
In wAIHA, pathogenic autoantibodies attack red blood cells at normal body temperature; severe cases can strain the heart and lungs and become life-threatening. Until now, doctors had no approved treatment and relied on corticosteroids and broad immunosuppressants. Imaavy is approved for patients aged 12 and older.
How it works
Imaavy blocks the neonatal Fc receptor (FcRn), a protein that normally recycles antibodies and keeps them in circulation. By blocking FcRn, more of the harmful antibodies are broken down — reducing the assault on red blood cells. In a Phase 2/3 study of 115 participants, the drug produced a statistically significant, durable hemoglobin response at 24 weeks versus placebo; the most common side effects were peripheral edema, diarrhea and fever.
Why it matters
“As the first therapy approved for wAIHA, Imaavy has the potential to redefine the management of” the disease, especially for uncontrolled cases, said J&J’s David Lee. It’s also a commercial priority: J&J projects the drug could reach $5 billion in peak sales across its multiple approved and investigational uses.